Bio Blast Gains 9%, Company Will President Final Phase 2 Trial Data At Industry Conference

Shares of Bio Blast Pharma Ltd ORPN were trading higher by more than 9 percent early Friday morning after the company announced it will present final data from a Phase 2 clinical study at the American Academy of Neurology (AAN) 2016 Annual Meeting.

Bio Blast Pharma is a clinical-stage biotechnology company that focuses on the treatment of orphan diseases. The company completed a Phase 2 six-month trial of its HOPEMD therapy in patients with oculopharyngeal muscular dystrophy (OPMD).

Related Link: Update: Bio Blast Pharma Improvements Observed In Multiple Secondary Efficacy Endpoints Related To Dysphagia, Muscle Strength And Function

OPMD is a rare progressive muscle-wasting disease characterized by swallowing difficulties, leading to the risk of aspiration of food into the lungs, weight loss and muscle weakness.

The meeting will take place April 15 to 21 in Vancouver, Canada.